Shinro Tachibana

Nocistatin, a peptide that blocks nociceptin action in pain transmission

Prolonged tissue damage or injury often leads to chronic pain states such that noxious stimuli evoke hyperalgesia and innocuous tactile stimuli evoke pain (allodynia),. The neuropeptide nociceptin,, also known as orphanin FQ (ref. 5), is an endogenous ligand for the orphan opioid-like receptor which induces both hyperalgesia and allodynia when administered by injection through the theca of the spinal cord into the subarachnoid space (that is, intrathecally),. Here we show that the nociceptin precursor, contains another biologically active peptide which we call nocistatin. Nocistatin blocks nociceptin-induced allodynia and hyperalgesia, and attenuates pain evoked by prostaglandin E2. It is the carboxy-terminal hexapeptide of nocistatin (Glu-Gln-Lys-Gln-Leu-Gln), which is conserved in bovine, human and murine species, that possesses allodynia-blocking activity. We have also isolated endogenous nocistatin from bovine brain. Furthermore, intrathecal pretreatment with anti-nocistatin antibody decreases the threshold for nociceptin-induced allodynia. Although nocistatin does not bind to the nociceptin receptor, it binds to the membrane of mouse brain and of spinal cord with high affinity. Our results show that nocistatin is a new biologically active peptide produced from the same precursor as nociceptin and indicate that these two peptides may play opposite roles in pain transmission.

Anti-nociceptive responses produced by human putative counterpart of nocistatin

b‐nocistatin is a heptadecapeptide produced from bovine prepronociceptin and blocks the induction of hyperalgesia and touch‐evoked pain (allodynia) by intrathecal administration of nociceptin or prostaglandin E2 (PGE2). Human prepronociceptin may generate a 30‐amino acid peptide different in length from b‐nocistatin. Here, we examine whether the human putative counterpart of nocistatin (h‐nocistatin) possessed the same biological activities as b‐nocistatin. Simultaneous intrathecal injection of h‐nocistatin in mice blocked the induction of allodynia by nociceptin and PGE2 in a dose‐dependent manner with ID50 values of 329 pg kg−1 and 16.6 ng kg−1, respectively. h‐nocistatin was about 10 times less potent than b‐nocistatin. h‐nocistatin also attenuated the nociceptin‐ and PGE2‐induced hyperalgesia. These results demonstrate that h‐nocistatin is biologically active and may be involved in the processing of pain at the spinal level in humans.

Expression and purification of a neuropeptide nocistatin using two related plant viral vectors

Both odontoglossum ringspot virus (ORSV) and tobacco mosaic virus (TMV) were investigated as expression viral vectors for the expression of a neuropeptide nocistatin. Chimeras of ORSV and TMV were constructed by fusion of 17 amino acids of mouse nocistatin (mNST) to the C-terminal of the coat protein (CP) gene via a Factor Xa cleavage linker to yield ORSV-mNST and TMV-mNST. Expression of the mNST peptide was demonstrated by immuno-transmission electron microscopy, western blot, mass spectrometry and radioimmunoassay. Serial passaging of the chimeric viruses revealed loss of mNST from TMV-mNST by the fifth passage. The mNST was maintained in ORSV-mNST throughout six passages. The mNST peptide could be effectively cleaved and purified from chimeric ORSV CP. To our knowledge, this is the first successful attempt in obtaining a complete peptide with no additional amino acid sequence after expression and purification through the use of either ORSV or TMV as vectors.

Supraspinal nocistatin and its amide derivative antagonize the hyperalgesic effects of nociceptin in mice

Nocistatin (NST) and nociceptin (NCP)/orphanin FQ are new neuropeptides derived from the same precursor molecule, and which are involved in pain transmission. Nocistatin has been shown to antagonize several effects of nociceptin by acting on a different receptor. We examined the effects of supraspinal nocistatin and nocistatin amide, and their interaction with nociceptin on nociceptive behavior in mice, using hotplate response times. We found that both nocistatin and nocistatin amide did not change the response time compared to control mice, whereas increasing doses of nociceptin caused progressive shortening of response times. Nocistatin and nocistatin amide were both able to antagonize the hyperalgesic effect of nociceptin. The effect of nocistatin amide was longer lasting and more potent, suggesting that the C-terminal free carboxyl group of nocistatin is not necessary for its biological activity, and that the amide derivative may be more biologically stable.

Changes in Amino Acids and Nitric Oxide Concentration in Cerebrospinal Fluid During Labor Pain

This study analyzes the relationship between amino acids and pain perception during active labor. Cerebrospinal fluid (CSF) levels of the excitatory amino acids (EAAs)—glutamate, aspartate and their amide forms, inhibitory amino acids (IAAs)—glycine, γ-amino butyric acid (GABA) and taurine and nitric oxide (NO) related compounds—arginine and citrulline (by-product of NO synthesis) were compared between pregnant women at term pregnancy with labor pain (nxa0=xa038) and without labor pain (Caesarian section; nxa0=xa030). The levels of aspartate, glycine, GABA and citrulline were significantly higher; whilst taurine was significantly lower in the labor pain group. These findings suggest that aspartate and NO are associated with labor pain. An inhibitory role for the IAA taurine and a pronociceptive role for glycine in labor pain are proposed.

Nocistatin and its derivatives antagonize the impairment of short-term acquisition induced by nociceptin

We studied the effects of human nocistatin, a mature form of human nocistatin of 17 amino acid length (nocistatin 17), and the amide derivative of nocistain 17 (nocistatin amide), and nociceptin/orphanin FQ on short-term acquisition in mice using a multi trial passive avoidance protocol. Nociceptin 1 nmol administered by i.c.v. injection 15 min beforehand increased the number of trials required to achieve the learning objective and decreased the step through latency times in the first, second and third test trials. Nocistatin and nocistatin 17 on their own did not affect acquisition, but were able at doses of 4 nmol to antagonize the impairment caused by nociceptin 1 nmol. Nocistatin amide on its own also did not impair acquisition and at a lower dose of 1 nmol was able to completely antagonize nociceptin. [N-Phe(1)]-nociceptin (1-13) amide, a selective opioid receptor-like 1 (ORL1) receptor antagonist, could also antagonize the effect of nociceptin, confirming that nociceptins effect is induced via the ORL1 receptor. The results support suggestions that both nocistatin and nociceptin have roles in learning and memory, with nocistatin working as a functional antagonist of nociceptin. The shorter mature human nocistatin peptide had similar activity to the larger peptide, and its amide derivative may be more potent.

Levels of neuropeptides nocistatin, nociceptin/orphanin FQ and their precursor protein in a rat neuropathic pain model

Neuropeptides nociceptin/orphanin FQ (N/OFQ) and nocistatin (NST) are related to pain modulation. The amounts of these peptides and their precursor protein, prepronociceptin (ppN/OFQ) in the brain, spinal cord and serum samples of rats with partial sciatic nerve ligation (PSNL) were compared with those in naïve rats using radioimmunoassay (RIA). There was a significant rise in the levels of ppN/OFQ, N/OFQ and NST in the brains of PSNL rats. Their spinal cords showed significantly increased ppN/OFQ and NST levels but no change in N/OFQ levels. The PSNL rats also had increased serum NST (statistically significant) and N/OFQ (statistically insignificant) with decreased ppN/OFQ suggesting important roles of these peptides in neuropathic pain mechanism.

Identification of mature nocistatin and nociceptin in human brain and cerebrospinal fluid by mass spectrometry combined with affinity chromatography and HPLC

Nocistatin (NST) and nociceptin/orphanin FQ (NCP) are two important bio-peptides derived from the precursor protein prepronociceptin (ppNCP), involved in several central nervous system (CNS) functions including pain transmission. Since the actual form of human NST in CNS is not fully characterized, we studied the structure of NST from human brain tissue and cerebrospinal fluid (CSF) samples. NST and NCP were isolated from human brain and CSF samples by affinity chromatography combined with HPLC. Mass spectrometry was used for the identification and characterization of the peptides. The total NST immunoreactivity was detected as 11.5+/-2.3 pmol/g tissue for the brain and 0.44 pmol/ml for the pooled CSF sample after the HPLC purification by radioimmunoassay. The presence of two different forms of mature nocistatin (NST-17 and NST-30) and a possible N-terminal methionine cleaved NST-29 were confirmed by both radioimmunoassay and mass spectrometry. Affinity chromatography, HPLC and mass spectrometry methods used in this study were highly sensitive and suitable for identification of actual chemical structures and quantification of very small amounts of peptides in biological samples. The present findings may help further for search for new treatment of neuropathic pain, which is often poorly managed by current therapies.

Localization of nocistatin-binding sites in mice brain and spinal cord using a biotinylated nocistatin probe.

Nocistatin and nociceptin/orphanin FQ are two neuropeptides processed from the same precursor prepronociceptin. They have opposing roles in nociception and several other biological functions. Whereas the location and structure of the nociceptin/orphanin FQ receptors has been defined, the location of the nocistatin receptors remains unknown. In the course of this study, we synthesized a novel probe for histochemistry by linking biotin to the N terminus of nocistatin, and purified this with high-pressure liquid chromatography and confirmed the structure by mass spectrometer. Using this probe, we found nocistatin-binding sites in the cerebral cortex and the dorsal horn nucleus of the spinal cord. We also found that the nocistatin-binding sites were in the cell body, whereas the nociceptin/orphanin FQ binding sites were on the fibrous processes.

Nocistatin attenuated the nociceptin induced c-Fos expression in the mouse hippocampus

Nocistatin and nociceptin/orphaninFQ (N/OFQ) are the two new peptides which may have roles in nociception, memory, anxiety, and other biological functions. Nocistatin acts as a functional antagonist to N/OFQ in several functions, but their neuro-anatomical sites of interaction are unknown. We investigated the effect of combined intracerebroventricular (i.c.v.) injection of nocistatin with N/OFQ, on N/OFQ induced c-Fos expression in the mouse hippocampus, using c-Fos immunohistochemistry. We found that co-injection of nocistatin with N/OFQ significantly attenuated N/OFQ induced c-Fos expression in the hippocampus.